Jointown Pharmaceutical Group Co., Ltd. Jointown Pharmaceutical Group Co., Ltd.

Jointown Pharmaceutical Group Co., Ltd.

600998

Classificação em ações #4349
Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution... Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution and supply chain business in China and internationally. It is also involved in general agency brand promotion; pharmaceutical industrial self-production and OEM; and pharmaceutical new retail and ten-thousand store alliance plan businesses. In addition, the company provides medical health and technology value-added services; and digital logistics and supply chain solutions. The company was founded in 1999 and is headquartered in Wuhan, China.
Preço da ação
$0.72167114
Valor de mercado
$3.64B
Variação (1 dia)
0.20%
Variação (1 ano)
3.63%
País
CN
Negociar Jointown Pharmaceutical Group Co., Ltd. (600998)

Categoria

Healthcare
Lucros da Jointown Pharmaceutical Group Co., Ltd. (600998)
Lucros em Jun 2026 TTM: $416.06M
De acordo com os últimos relatórios financeiros da Jointown Pharmaceutical Group Co., Ltd., os ganhos atuais da empresa são de $416.06M. Em 2023, a empresa teve ganhos de $422.52M, um aumento em relação a aos ganhos de 2022, que foram de $411.44M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Jointown Pharmaceutical Group Co., Ltd. de 2007 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $416.06M -16.51%
2024 $498.34M 17.95%
2023 $422.52M 2.69%
2022 $411.44M -22.25%
2021 $529.16M -20.24%
2020 $663.43M 99.34%
2019 $332.81M 25.04%
2018 $266.16M -10.03%
2017 $295.83M 85.77%
2016 $159.25M 8.19%
2015 $147.19M 21.01%
2014 $121.63M 21.59%
2013 $100.03M 12.91%
2012 $88.59M 14.06%
2011 $77.67M 7.20%
2010 $72.46M 31.02%
2009 $55.30M 43.01%
2008 $38.67M 39.46%
2007 $27.73M 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
$6.46B 1,452.19%
US
- -
US
$2.17B 422.52%
US
- -
US
$708.86M 70.38%
AU